Trial · NCT03434041
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28) | Intranasal Esketamine + Oral Antidepressant (AD) | -10.1 | Standard Deviation 10.80 | Units on a Scale | |
| Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28) | Intranasal Placebo + Oral AD | -8.1 | Standard Deviation 10.26 | Units on a Scale | |
| Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2) | Intranasal Esketamine + Oral Antidepressant (AD) | -8.0 | Standard Deviation 9.01 | Units on a Scale | |
| Change From Baseline in Depressive Symptoms as Measured by the MADRS Total Score to 24 Hours Post First Dose (Day 2) | Intranasal Placebo + Oral AD | -4.4 | Standard Deviation 7.66 | Units on a Scale | |
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28) | Intranasal Esketamine + Oral Antidepressant (AD) | -6.3 | Standard Deviation 7.54 | Units on a Scale | |
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score to the End of Double-blind Treatment Phase (Day 28) | Intranasal Placebo + Oral AD | -5.3 | Standard Deviation 7.03 | Units on a Scale | |
| Percentage of Participants With Onset of Clinical Response | Intranasal Esketamine + Oral Antidepressant (AD) | 6.5 | Percentage of participants | ||
| Percentage of Participants With Onset of Clinical Response | Intranasal Placebo + Oral AD | 1.6 | Percentage of participants | ||
| Percentage of Responders at the End of Double-blind Treatment Phase (Day 28) | Intranasal Esketamine + Oral Antidepressant (AD) | 19.3 | Percentage of Responders | ||
| Percentage of Responders at the End of Double-blind Treatment Phase (Day 28) | Intranasal Placebo + Oral AD | 16.0 | Percentage of Responders | ||
| Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28) | Intranasal Esketamine + Oral Antidepressant (AD) | 12.8 | Percentage of Participants | ||
| Percentage of Participants in Remission at the End of Double-blind Treatment Phase (Day 28) | Intranasal Placebo + Oral AD | 10.4 | Percentage of Participants | ||
| Percentage of Participants With Sustained Remission | Intranasal Esketamine + Oral Antidepressant (AD) | 5.6 | Percentage of Participants | ||
| Percentage of Participants With Sustained Remission | Intranasal Placebo + Oral AD | 6.3 | Percentage of Participants | ||
| Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | Intranasal Esketamine + Oral Antidepressant (AD) | -1.0 | Full Range -5 to 1 | Units on a Scale | |
| Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | Intranasal Placebo + Oral AD | -1.0 | Full Range -5 to 1 | Units on a Scale | |
| Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | Intranasal Esketamine + Oral Antidepressant (AD) | -4.3 | Standard Deviation 5.65 | Units on a Scale | |
| Change From Baseline in Generalized Anxiety Disorder 7-item (GAD-7) Scale Score up to the Endpoint (Double-blind Treatment Phase [Day 28]) | Intranasal Placebo + Oral AD | -2.9 | Standard Deviation 5.28 | Units on a Scale | |
Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index | Intranasal Esketamine + Oral Antidepressant (AD) | 0.152 | Standard Deviation 0.2294 | Units on a Scale | |
Change From Baseline in Participant-Reported Health-Related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score up to the Endpoint (Double-blind Treatment Phase [Day 28]): Health Status Index | Intranasal Placebo + Oral AD | 0.103 | Standard Deviation 0.2084 | Units on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03434041/results